Tatiana Verzhbitskaya
Tatiana Verzhbitskaya has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandr Mikhailovich Popov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela St., Moscow 117198, Russia
15 shared publications - Larisa G. Fechina
Sverdlovsk Regional Children’s Clinical Hospital No. 1
15 shared publications - Grigoriy Anatolyevich Tsaur
Ural State Medical University
13 shared publications Т. Ю. Вержбицкая
ГАУЗ СО «Областная детская клиническая больница»; ГАУЗ СО «Институт медицинских клеточных технологий
12 shared publications- Yulia Olshanskaya
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
7 shared publications - Galina. A. Novichkova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela St., Moscow 117198, Russia
6 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 159-169
Results of quality control/quality assurance study for the comparability of the results of flow cytometric minimal residual disease studies in B-lineage acute lymphoblastic leukemia in Russian laboratories of the Moscow–Berlin study group
Aim of the study – comparison of results of flow cytometric minimal residual disease (MRD) detection in B-lineage acute lymphoblastic leukemia in two Russian laboratories of the Moscow–Berlin study group. Materials and methods. Ring trial was performed in three rounds. Four flow cytometry specialist from Dmitry Rogachev Center (Moscow) and two from Regional Children Hospital (Ekaterinburg) were suggested to analyze cytometric files of 70 studies of bone marrow samples obtained at various time-points during different treatment phases. Results and discussion. Although false-positive and false-negative results were obtained by single specialists in exact cases, the overall comparability of MRD data was very high. Found discrepancies were observed mainly in cases with very low MRD burden (below 0.01%). Also discordant results were observed in patients with CD10-negative immunophenotype. Nevertheless, in all samples the majority of the documented results were right. Presence of the most experienced expert in each laboratory, who is responsible for the final conclusion on MRD samples, led to the high inter-laboratory concordance. Conclusion. Therefore, discussion of all complicated cases with the most experienced specialists, centralization of the primary immunophenotyping, clinical application of the most reproducible MRD thresholds, as well as further improvement of flow cytometry methodology and technology harmonization will allow achieving perfect reproducibility of the flow cytometric MRD detection in patients with B-lineage acute lymphoblastic leukemia.
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 159-169
Open AccessResults of quality control/quality assurance study for the comparability of the results of flow cytometric minimal residual disease studies in B-lineage acute lymphoblastic leukemia in Russian laboratories of the Moscow–Berlin study group
Aim of the study – comparison of results of flow cytometric minimal residual disease (MRD) detection in B-lineage acute lymphoblastic leukemia in two Russian laboratories of the Moscow–Berlin study group. Materials and methods. Ring trial was performed in three rounds. Four flow cytometry specialist from Dmitry Rogachev Center (Moscow) and two from Regional Children Hospital (Ekaterinburg) were suggested to analyze cytometric files of 70 studies of bone marrow samples obtained at various time-points during different treatment phases. Results and discussion. Although false-positive and false-negative results were obtained by single specialists in exact cases, the overall comparability of MRD data was very high. Found discrepancies were observed mainly in cases with very low MRD burden (below 0.01%). Also discordant results were observed in patients with CD10-negative immunophenotype. Nevertheless, in all samples the majority of the documented results were right. Presence of the most experienced expert in each laboratory, who is responsible for the final conclusion on MRD samples, led to the high inter-laboratory concordance. Conclusion. Therefore, discussion of all complicated cases with the most experienced specialists, centralization of the primary immunophenotyping, clinical application of the most reproducible MRD thresholds, as well as further improvement of flow cytometry methodology and technology harmonization will allow achieving perfect reproducibility of the flow cytometric MRD detection in patients with B-lineage acute lymphoblastic leukemia.
- 25 November 2025
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 14 (3)
Pediatric B-lineage acute lymphoblastic leukemia with CRLF2 rearrangements. Own experience in molecular genetic diagnostics and patient monitoring
B-lineage acute lymphoblastic leukemia (ALL) with CRLF2 rearrangements is characterized by high genetic heterogeneity and can be accompanied with mutations in the JAK-STAT signaling pathway, intrachromosomal amplification of chromosome 21 (iAMP21), dic (9;20), as well as IKZF1 deletions and has an unfavorable outome. Purpose. To characterize clinical, immunological and molecular genetic features of children with B-lineage ALL with CRLF2 rearrangements. Materials and methods. The study included 958 children aged 1-18 years with primarily diagnosed B-lineage ALL. Among them, a search for CRLF2 rearrangements was carried out using the fluorescence in situ hybridization, and the spectrum of genetic aberrations was analyzed using multiplex ligase-dependent probe amplification (MLPA) and targeted next-generation sequencing of RNA. Results. CRLF2 rearrangements were detected in 58 (6.1%) patients, including 42 with P2RY8::CRLF2 (72.4%) and 16 with IGH::CRLF2 (27.6%). Patients with IGH::CRLF2 fusion gene were significantly older, more often had an initial WBC ≥50×109/L and were significantly more often classified as high-risk according to the criteria of the US National Cancer Institute, however no significant differences in survival and cumulative incidence of relapse between these groups were found. JAK1/2 mutations were detected in 14.0% of CRLF2-rearranged patients, RAS family gene mutations in 23.3% and PAX5 alterations (both point mutations and fusion genes) in 18.6%. Seventeen patients (37.7%) with IKZF1 deletions were identified, while 10 of them (22.2%) had the IKZF1plus profile. With a median follow-up time of 5.3 years, the event-free survival of patients with ALL and CRLF2 rearrangements was 0.49 (standard error (SE) 0.22) and the cumulative incidence of relapse was 0.46 (SE 0.12). The most unfavorable outcome was observed in patients with IKZF1plus profile. Of note, the persistence of minimal residual disease at the end of remission induction did not have a statistically significant impact on the prognosis of patients with ALL and CRLF2 rearrangements. Conclusions. In our cohort of pediatric patients with B-lineage ALL the incidence of CRLF2 rearrangements was 6.1%. These patients showed significant genetic heterogeneity and unfavorable outcome.
- 25 November 2025
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 14 (3)
Pediatric B-lineage acute lymphoblastic leukemia with CRLF2 rearrangements. Own experience in molecular genetic diagnostics and patient monitoring
B-lineage acute lymphoblastic leukemia (ALL) with CRLF2 rearrangements is characterized by high genetic heterogeneity and can be accompanied with mutations in the JAK-STAT signaling pathway, intrachromosomal amplification of chromosome 21 (iAMP21), dic (9;20), as well as IKZF1 deletions and has an unfavorable outome. Purpose. To characterize clinical, immunological and molecular genetic features of children with B-lineage ALL with CRLF2 rearrangements. Materials and methods. The study included 958 children aged 1-18 years with primarily diagnosed B-lineage ALL. Among them, a search for CRLF2 rearrangements was carried out using the fluorescence in situ hybridization, and the spectrum of genetic aberrations was analyzed using multiplex ligase-dependent probe amplification (MLPA) and targeted next-generation sequencing of RNA. Results. CRLF2 rearrangements were detected in 58 (6.1%) patients, including 42 with P2RY8::CRLF2 (72.4%) and 16 with IGH::CRLF2 (27.6%). Patients with IGH::CRLF2 fusion gene were significantly older, more often had an initial WBC ≥50×109/L and were significantly more often classified as high-risk according to the criteria of the US National Cancer Institute, however no significant differences in survival and cumulative incidence of relapse between these groups were found. JAK1/2 mutations were detected in 14.0% of CRLF2-rearranged patients, RAS family gene mutations in 23.3% and PAX5 alterations (both point mutations and fusion genes) in 18.6%. Seventeen patients (37.7%) with IKZF1 deletions were identified, while 10 of them (22.2%) had the IKZF1plus profile. With a median follow-up time of 5.3 years, the event-free survival of patients with ALL and CRLF2 rearrangements was 0.49 (standard error (SE) 0.22) and the cumulative incidence of relapse was 0.46 (SE 0.12). The most unfavorable outcome was observed in patients with IKZF1plus profile. Of note, the persistence of minimal residual disease at the end of remission induction did not have a statistically significant impact on the prognosis of patients with ALL and CRLF2 rearrangements. Conclusions. In our cohort of pediatric patients with B-lineage ALL the incidence of CRLF2 rearrangements was 6.1%. These patients showed significant genetic heterogeneity and unfavorable outcome.
- Open Access
- 8 September 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 102-115
Additional genetic aberrations detected by fluorescence in situ hybridization in children with acute lymphoblastic leukemia and the t(12;21)(p13;q22)/ETV6::RUNX1 translocation: an association with initial clinical and laboratory findings and response to therapy
Translocation t(12;21)(p13;q22)/ETV6::RUNX1 is among the most common genetic aberrations in pediatric B-cell precursor acute lymphoblastic leukekian (BCP-ALL). This translocation is often combined with ETV6 and/or RUNX1 copy number variations. Fluorescence in situ hybridization (FISH) technique, which is widely used to reveal the presence of t(12;21)(p13;q22), also allows the detection of these additional genetic aberrations (FISH patterns). The aim of this study was to provide detailed characteristics of FISH patterns in patients with BCP-ALL and the t(12;21)(p13;q22)/ETV6::RUNX1 translocation. In our study we enrolled 241 patients with t(12;21)-positive ALL who had undergone testing with a dual-color double-fusion FISH assay between 2008 and 2023. This study was approved by the Independent Ethics Committee and the Academic Council of the Research Institute of Medical Cell Technologies (Ekaterinburg). A single FISH pattern (monoclonal cases) was identified in 200 patients (83.0%), 2 or more patterns (polyclonal cases) were detected in 41 (17.0%) patients. The majority of polyclonal cases (n = 39; 95.1%) exhibited 2 patterns. The most common secondary genetic alteration was ETV6 deletion (n = 105; 43.5%). Less common aberrations included an additional copy of RUNX1 (n = 97; 40.2%), a combination of ETV6 deletion and an additional copy of RUNX1 (n = 27; 11.2%), and an additional copy of ETV6 (n = 5; 2.0%). The number of the patients with one FISH pattern that did not contain any additional genetic aberrations as a result of a reciprocal translocation (2F1G1R) was relatively small (n = 35; 17.5%). We identified 5 prognostically unfavorable FISH patterns associated with a high risk of relapse. These included cases with simultaneous presence of ETV6 and RUNX1 additional copies (pattern 2F2G2R), isolated additional copies of RUNX1 (pattern 2F2R-3F2R) or ETV6 (pattern 1F1G2R-2F2G4R), a partial deletion of ETV6 (pattern 2F1Gdim1R) and a non-reciprocal translocation of t(12;21) (pattern 1F1R-1F1G1R). Grouping these unfavorable prognostic FISH patterns together made it possible to predict 6 (46%) out of 13 relapses that occurred in the patients during the study period. It is important to highlight that the number of the patients with unfavorable FISH patterns and initial leukocytosis of 30 × 109 leukocytes/L did not differ significantly from the rest of the group. Another important observation was that the patients with prognostically unfavorable FISH patterns responded well to induction therapy, as assessed both by cytological examination of blood and bone marrow smears on days 8, 15, and 36 of therapy and by MRD response at the end of induction therapy according to the ALL-MB 2015 protocol. A comparison of FISH patterns detected at initial diagnosis and at relapse showed that only 6 (50%) out of 12 cases who had undergone FISH testing at both time points remained stable. In conclusion, BCP-ALL with the translocation t(12;21)(p13;q22)/ETV6::RUNX1 was characterized by a vast variety of secondary genetic aberrations detected by FISH, the most prevalent of which was ETV6 deletion. A group of unfavorable FISH patterns identified in our study warrants further investigation in a larger cohort of ALL patients for their possible re-stratification so that they could receive more intensive treatment.
- 8 September 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 102-115
Open AccessAdditional genetic aberrations detected by fluorescence in situ hybridization in children with acute lymphoblastic leukemia and the t(12;21)(p13;q22)/ETV6::RUNX1 translocation: an association with initial clinical and laboratory findings and response to therapy
Translocation t(12;21)(p13;q22)/ETV6::RUNX1 is among the most common genetic aberrations in pediatric B-cell precursor acute lymphoblastic leukekian (BCP-ALL). This translocation is often combined with ETV6 and/or RUNX1 copy number variations. Fluorescence in situ hybridization (FISH) technique, which is widely used to reveal the presence of t(12;21)(p13;q22), also allows the detection of these additional genetic aberrations (FISH patterns). The aim of this study was to provide detailed characteristics of FISH patterns in patients with BCP-ALL and the t(12;21)(p13;q22)/ETV6::RUNX1 translocation. In our study we enrolled 241 patients with t(12;21)-positive ALL who had undergone testing with a dual-color double-fusion FISH assay between 2008 and 2023. This study was approved by the Independent Ethics Committee and the Academic Council of the Research Institute of Medical Cell Technologies (Ekaterinburg). A single FISH pattern (monoclonal cases) was identified in 200 patients (83.0%), 2 or more patterns (polyclonal cases) were detected in 41 (17.0%) patients. The majority of polyclonal cases (n = 39; 95.1%) exhibited 2 patterns. The most common secondary genetic alteration was ETV6 deletion (n = 105; 43.5%). Less common aberrations included an additional copy of RUNX1 (n = 97; 40.2%), a combination of ETV6 deletion and an additional copy of RUNX1 (n = 27; 11.2%), and an additional copy of ETV6 (n = 5; 2.0%). The number of the patients with one FISH pattern that did not contain any additional genetic aberrations as a result of a reciprocal translocation (2F1G1R) was relatively small (n = 35; 17.5%). We identified 5 prognostically unfavorable FISH patterns associated with a high risk of relapse. These included cases with simultaneous presence of ETV6 and RUNX1 additional copies (pattern 2F2G2R), isolated additional copies of RUNX1 (pattern 2F2R-3F2R) or ETV6 (pattern 1F1G2R-2F2G4R), a partial deletion of ETV6 (pattern 2F1Gdim1R) and a non-reciprocal translocation of t(12;21) (pattern 1F1R-1F1G1R). Grouping these unfavorable prognostic FISH patterns together made it possible to predict 6 (46%) out of 13 relapses that occurred in the patients during the study period. It is important to highlight that the number of the patients with unfavorable FISH patterns and initial leukocytosis of 30 × 109 leukocytes/L did not differ significantly from the rest of the group. Another important observation was that the patients with prognostically unfavorable FISH patterns responded well to induction therapy, as assessed both by cytological examination of blood and bone marrow smears on days 8, 15, and 36 of therapy and by MRD response at the end of induction therapy according to the ALL-MB 2015 protocol. A comparison of FISH patterns detected at initial diagnosis and at relapse showed that only 6 (50%) out of 12 cases who had undergone FISH testing at both time points remained stable. In conclusion, BCP-ALL with the translocation t(12;21)(p13;q22)/ETV6::RUNX1 was characterized by a vast variety of secondary genetic aberrations detected by FISH, the most prevalent of which was ETV6 deletion. A group of unfavorable FISH patterns identified in our study warrants further investigation in a larger cohort of ALL patients for their possible re-stratification so that they could receive more intensive treatment.
- Open Access
- 19 April 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (1) , 219-230
Immunophenotyping in the diagnosis of acute leukemias of ambiguous lineage. The results of centralized diagnosis and practical guidelines
Acute leukemias of ambiguous lineage (ALAL) are rare acute leukemias (AL) that exhibit specific features of more than one hematopoietic lineage or show no distinct evidence of lineage differentiation. Immunophenotyping plays a key role in the diagnosis and classification of ALAL. Despite the availability of diagnostic criteria for ALAL proposed by different expert groups, the accurate diagnosis of ALAL representing a rare and heterogeneous group of diseases remains a challenge. In this paper, we present a brief analysis of 97 pediatric ALAL cases. Such a large cohort of cases with ALAL (ALALs comprising less than 1 % of all pediatric AL) was obtained as a result of the centralized diagnosis of AL. With regard to the obtained results, we have developed the guidelines for the interpretation of the results of immunophenotyping in the diagnosis of ALAL and for the integration of findings from flow cytometry, cytomorphology and genetic testing for the accurate diagnosis and classification of this group of AL.
- 19 April 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (1) , 219-230
Open AccessImmunophenotyping in the diagnosis of acute leukemias of ambiguous lineage. The results of centralized diagnosis and practical guidelines
Acute leukemias of ambiguous lineage (ALAL) are rare acute leukemias (AL) that exhibit specific features of more than one hematopoietic lineage or show no distinct evidence of lineage differentiation. Immunophenotyping plays a key role in the diagnosis and classification of ALAL. Despite the availability of diagnostic criteria for ALAL proposed by different expert groups, the accurate diagnosis of ALAL representing a rare and heterogeneous group of diseases remains a challenge. In this paper, we present a brief analysis of 97 pediatric ALAL cases. Such a large cohort of cases with ALAL (ALALs comprising less than 1 % of all pediatric AL) was obtained as a result of the centralized diagnosis of AL. With regard to the obtained results, we have developed the guidelines for the interpretation of the results of immunophenotyping in the diagnosis of ALAL and for the integration of findings from flow cytometry, cytomorphology and genetic testing for the accurate diagnosis and classification of this group of AL.
- Open Access
- 8 April 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (2) , 34-39
A comparison of ex vivo and in vivo T-cell depletion for hematopoietic stem cell transplantation in children with malignant blood disorders
A decrease in T cell alloreactivity following hematopoietic stem cell transplantation (HSCT) can be achieved via the depletion of TCRab+ and CD19+ lymphocytes or post-transplant therapy with high-dose cyclophosphamide (PTCy). The purpose of this study was to analyze HSCT outcomes according to the type of lymphocyte depletion. In our non-randomized retrospective study, we analyzed the results of 118 HSCTs performed in 107 patients with malignant blood disorders at the Center for Pediatric Oncology and Hematology of the Regional Children’s Clinical Hospital (Yekaterinburg) from 2010 to 2023. The patients were divided into 2 groups: those who had received ex vivo TCRab+/CD19+ depletion using the CliniMACS technology (n = 75; Group 1) and those who had received in vivo depletion using PTCy at a dose of 50 mg/kg (n = 43; Group 2). The study was approved by the Independent Ethics Committee and the Scientific Council of the Institute of Medical Cell Technologies (Yekaterinburg). Informed consent for the research and treatment was obtained from each patient and their legal representatives. Even though the patients from the TCRab+/CD19+ depletion group showed a better engraftment rate (median time: 12 days) than the subjects from the PTCy group (median time: 18 days) (p < 0.0001), there was no statistically significant difference in the cumulative incidence of cytomegalovirus and herpesvirus type 6 infection reactivation post-transplant between the two study groups. The cytomegalovirus reactivation rate was 0.467 and 0.466 in Group 1 and 2 respectively (p = 0.89), while for herpesvirus type 6 the reactivation rate was 0.360 and 0.240 respectively (p = 0.13). There were no significant differences in the cumulative incidence of acute graft-versus-host disease (GVHD) in the two groups by Day +100 (0.294 and 0.419 in Group 1 and 2 respectively; p = 0.77); neither was there any difference in the incidence of severe acute GVHD (0.067 and 0.093 respectively; p = 0.11). The incidence of chronic GVHD was 0.12 in the TCRab+/CD19+ depletion group and 0.26 in the PTCy group (p = 0.11). The event-free survival, overall survival and cumulative incidence of relapse did not differ between the studied groups either. The two methods of the depletion of unwanted T-cell populations showed a comparable effectiveness. The choice between them should be based on factors related to the biological characteristics of the disease and the clinical status of a patient. The availability of different depletion methods at a single transplant center helps to choose the optimal treatment option for patients who are in need of HSCT.
- 8 April 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (2) , 34-39
Open AccessA comparison of ex vivo and in vivo T-cell depletion for hematopoietic stem cell transplantation in children with malignant blood disorders
A decrease in T cell alloreactivity following hematopoietic stem cell transplantation (HSCT) can be achieved via the depletion of TCRab+ and CD19+ lymphocytes or post-transplant therapy with high-dose cyclophosphamide (PTCy). The purpose of this study was to analyze HSCT outcomes according to the type of lymphocyte depletion. In our non-randomized retrospective study, we analyzed the results of 118 HSCTs performed in 107 patients with malignant blood disorders at the Center for Pediatric Oncology and Hematology of the Regional Children’s Clinical Hospital (Yekaterinburg) from 2010 to 2023. The patients were divided into 2 groups: those who had received ex vivo TCRab+/CD19+ depletion using the CliniMACS technology (n = 75; Group 1) and those who had received in vivo depletion using PTCy at a dose of 50 mg/kg (n = 43; Group 2). The study was approved by the Independent Ethics Committee and the Scientific Council of the Institute of Medical Cell Technologies (Yekaterinburg). Informed consent for the research and treatment was obtained from each patient and their legal representatives. Even though the patients from the TCRab+/CD19+ depletion group showed a better engraftment rate (median time: 12 days) than the subjects from the PTCy group (median time: 18 days) (p < 0.0001), there was no statistically significant difference in the cumulative incidence of cytomegalovirus and herpesvirus type 6 infection reactivation post-transplant between the two study groups. The cytomegalovirus reactivation rate was 0.467 and 0.466 in Group 1 and 2 respectively (p = 0.89), while for herpesvirus type 6 the reactivation rate was 0.360 and 0.240 respectively (p = 0.13). There were no significant differences in the cumulative incidence of acute graft-versus-host disease (GVHD) in the two groups by Day +100 (0.294 and 0.419 in Group 1 and 2 respectively; p = 0.77); neither was there any difference in the incidence of severe acute GVHD (0.067 and 0.093 respectively; p = 0.11). The incidence of chronic GVHD was 0.12 in the TCRab+/CD19+ depletion group and 0.26 in the PTCy group (p = 0.11). The event-free survival, overall survival and cumulative incidence of relapse did not differ between the studied groups either. The two methods of the depletion of unwanted T-cell populations showed a comparable effectiveness. The choice between them should be based on factors related to the biological characteristics of the disease and the clinical status of a patient. The availability of different depletion methods at a single transplant center helps to choose the optimal treatment option for patients who are in need of HSCT.
- Open Access
- 20 December 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (4) , 79-89
Flow cytometric and cytomorphological definition of remission achievement in children with B-lineage acute lymphoblastic leukemia
The achievement of remission at the end of induction (EOI) chemotherapy in patients with acute lymphoblastic leukemia (ALL) is the key parameter of treatment effectiveness evaluation. The aim of the study – defining complete remission by multicolor flow cytometry (MFC) and bone marrow (BM) cytomorphology (CM) at the EOI chemotherapy in children with B-lineage ALL. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study included patients of “ALL-MB 2008” and “ALL-MB 2015” trials for whom minimal residual disease (MRD) was evaluated by MFC at the EOI simultaneously with CM BM investigation. Less than 5% blasts in BM and MRD 1% were established as the remission achievement criteria for CM and MFC respectively. The study group included 1498 children aged from 1 to 18 years (median age was 4 years and 11 months) with B-cell precursor ALL. The overall concordance of MFC and CM was found to be 96.1% (1440 of 1498 patients). In 36 (2.4%) children with MRD ≥ 1%, M1 BM status was observed. In contrast, in 22 (1.5%) patients with M2/M3 BM status by CM, MRD value was below 1%. Treatment outcome was analyzed in 522 patients of “ALL-MB 2008” trial. Children with M2/M3 BM, as well as with MRD ≥ 1% demonstrated dramatically inferior outcome, in comparison to those who achieved remission. The presence of at least one of the mentioned criteria (M2/M3 status by CM or MRD ≥ 1% by MFC) defined a group of 23 (4.4%) patients with very low event-free survival (34.9%, standard error 11.0%) and very high cumulative incidence of relapse (56.4%, standard error 12.0%). For the evaluation of remission achievement, MFC and CM should be applied simultaneously at the EOI. High leukemic burden found by any of these methods is the clear definition of induction failure. MRD detection at the EOI should be implemented in any modern treatment protocol as an obligatory stage of treatment response monitoring and final risk group stratification. Considering the crucial importance of the MRD detection results, this study must be performed only in the reference laboratories of the study groups.
- 20 December 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (4) , 79-89
Open AccessFlow cytometric and cytomorphological definition of remission achievement in children with B-lineage acute lymphoblastic leukemia
The achievement of remission at the end of induction (EOI) chemotherapy in patients with acute lymphoblastic leukemia (ALL) is the key parameter of treatment effectiveness evaluation. The aim of the study – defining complete remission by multicolor flow cytometry (MFC) and bone marrow (BM) cytomorphology (CM) at the EOI chemotherapy in children with B-lineage ALL. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study included patients of “ALL-MB 2008” and “ALL-MB 2015” trials for whom minimal residual disease (MRD) was evaluated by MFC at the EOI simultaneously with CM BM investigation. Less than 5% blasts in BM and MRD 1% were established as the remission achievement criteria for CM and MFC respectively. The study group included 1498 children aged from 1 to 18 years (median age was 4 years and 11 months) with B-cell precursor ALL. The overall concordance of MFC and CM was found to be 96.1% (1440 of 1498 patients). In 36 (2.4%) children with MRD ≥ 1%, M1 BM status was observed. In contrast, in 22 (1.5%) patients with M2/M3 BM status by CM, MRD value was below 1%. Treatment outcome was analyzed in 522 patients of “ALL-MB 2008” trial. Children with M2/M3 BM, as well as with MRD ≥ 1% demonstrated dramatically inferior outcome, in comparison to those who achieved remission. The presence of at least one of the mentioned criteria (M2/M3 status by CM or MRD ≥ 1% by MFC) defined a group of 23 (4.4%) patients with very low event-free survival (34.9%, standard error 11.0%) and very high cumulative incidence of relapse (56.4%, standard error 12.0%). For the evaluation of remission achievement, MFC and CM should be applied simultaneously at the EOI. High leukemic burden found by any of these methods is the clear definition of induction failure. MRD detection at the EOI should be implemented in any modern treatment protocol as an obligatory stage of treatment response monitoring and final risk group stratification. Considering the crucial importance of the MRD detection results, this study must be performed only in the reference laboratories of the study groups.
- Open Access
- 3 October 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (3) , 199-209
Minimal residual disease monitoring in B-lineage acute lymphoblastic leukemia using flow cytometry. Guidelines of the Russian-Belarusian multicenter group for pediatric acute leukemia studies
Multicolor flow cytometry is now routinely used in laboratory practice for minimal residual disease (MRD) monitoring in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). This article describes the methodology of MRD detection in BCP-ALL using flow cytometry as recommended by the Russian-Belarusian multicenter group for pediatric acute leukemia studies. This wellharmonized approach includes recommendations for the choice of monoclonal antibodies, sample preparation, cytometer setup, flow cytometry data analysis and interpretation as well as for reporting. These guidelines allow application of multicolor flow cytometry for MRD monitoring in BCP-ALL in children and adults both in local laboratories and in multicenter settings in prospective clinical trials.
- 3 October 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (3) , 199-209
Open AccessMinimal residual disease monitoring in B-lineage acute lymphoblastic leukemia using flow cytometry. Guidelines of the Russian-Belarusian multicenter group for pediatric acute leukemia studies
Multicolor flow cytometry is now routinely used in laboratory practice for minimal residual disease (MRD) monitoring in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). This article describes the methodology of MRD detection in BCP-ALL using flow cytometry as recommended by the Russian-Belarusian multicenter group for pediatric acute leukemia studies. This wellharmonized approach includes recommendations for the choice of monoclonal antibodies, sample preparation, cytometer setup, flow cytometry data analysis and interpretation as well as for reporting. These guidelines allow application of multicolor flow cytometry for MRD monitoring in BCP-ALL in children and adults both in local laboratories and in multicenter settings in prospective clinical trials.
- Open Access
- 12 May 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (2) , 63-72
The use of blinatumomab in children with de novo Ph-negative B-lineage acute lymphoblastic leukemia and slow clearance of minimal residual disease
Children with acute lymphoblastic leukemia (ALL) and slow clearance of minimal residual disease (MRD) demonstrate a significantly worse outcome as compared to those with fast response to chemotherapy. Bispecific monoclonal antibody blinatumomab is the key drug for CD19-directed immunotherapy which opens wide opportunities for the elimination of MRD in patients with B-cell precursor ALL (BCP-ALL). Aim of the study – to evaluate the effectiveness of blinatumomab for MRD elimination in children with BCP-ALL and slow MRD clearance treated by the “ALL-MB 2015” protocol. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Patients from the “ALL-MB 2015” trial who demonstrated slow MRD clearance at the end of induction were included in the current study. MRD monitoring was performed by multicolor flow cytometry modified with respect to possible CD19 loss during targeted treatment. Threshold of 0.001% was used for MRD positivity definition. Between February 2020 and August 2023, 228 children with de novo Ph-negative KMT2A-negative BCP-ALL were defined as slow MRD responders according to the criteria of the “Moscow-Berlin” group. Fifty of them were treated with blinatumomab because of slow MRD clearance. Blinatumomab course was given immediately after induction in 23 children, after Consolidation I – in 14 patients, after Consolidation II – in 11 patients, while two children received immunotherapy prior to maintenance. After completion of blinatumomab course, 23 patients continued protocol treatment, 21 received maintenance only, two were treated with high-risk blocks and four received hematopoietic stem cell transplantation. Only 2 of 50 (4.0 %) patients remained MRD-positive after completion of blinatumomab course. By the end of December 2023, only two adverse events were registered: one relapse and one remission death. Two-year event-free survival was 94.7 % (standard error 3.6 %), while cumulative incidence of relapse was 2.6 % (standard error 2.7 %). Outcome in these 50 patients was much better in comparison with 178 children with a slow MRD response who did not receive blinatumomab. The use of blinatumomab in children with de novo Ph-negative BCP-ALL with slow MRD clearance allows achieving MRD-negative remission in nearly all cases. Although a longer follow-up is necessary for the reliable conclusion of CD19-directed therapy effectiveness, the promising results are obtained in the current study in this unfavorable patient group.
- 12 May 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (2) , 63-72
Open AccessThe use of blinatumomab in children with de novo Ph-negative B-lineage acute lymphoblastic leukemia and slow clearance of minimal residual disease
Children with acute lymphoblastic leukemia (ALL) and slow clearance of minimal residual disease (MRD) demonstrate a significantly worse outcome as compared to those with fast response to chemotherapy. Bispecific monoclonal antibody blinatumomab is the key drug for CD19-directed immunotherapy which opens wide opportunities for the elimination of MRD in patients with B-cell precursor ALL (BCP-ALL). Aim of the study – to evaluate the effectiveness of blinatumomab for MRD elimination in children with BCP-ALL and slow MRD clearance treated by the “ALL-MB 2015” protocol. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Patients from the “ALL-MB 2015” trial who demonstrated slow MRD clearance at the end of induction were included in the current study. MRD monitoring was performed by multicolor flow cytometry modified with respect to possible CD19 loss during targeted treatment. Threshold of 0.001% was used for MRD positivity definition. Between February 2020 and August 2023, 228 children with de novo Ph-negative KMT2A-negative BCP-ALL were defined as slow MRD responders according to the criteria of the “Moscow-Berlin” group. Fifty of them were treated with blinatumomab because of slow MRD clearance. Blinatumomab course was given immediately after induction in 23 children, after Consolidation I – in 14 patients, after Consolidation II – in 11 patients, while two children received immunotherapy prior to maintenance. After completion of blinatumomab course, 23 patients continued protocol treatment, 21 received maintenance only, two were treated with high-risk blocks and four received hematopoietic stem cell transplantation. Only 2 of 50 (4.0 %) patients remained MRD-positive after completion of blinatumomab course. By the end of December 2023, only two adverse events were registered: one relapse and one remission death. Two-year event-free survival was 94.7 % (standard error 3.6 %), while cumulative incidence of relapse was 2.6 % (standard error 2.7 %). Outcome in these 50 patients was much better in comparison with 178 children with a slow MRD response who did not receive blinatumomab. The use of blinatumomab in children with de novo Ph-negative BCP-ALL with slow MRD clearance allows achieving MRD-negative remission in nearly all cases. Although a longer follow-up is necessary for the reliable conclusion of CD19-directed therapy effectiveness, the promising results are obtained in the current study in this unfavorable patient group.
- Open Access
- 14 February 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (1) , 165-177
Flow cytometry in acute leukemia diagnostics. Guidelines of Russian-Belarusian multicenter group for pediatric leukemia studies
Flow cytometry is one of the key technologies for acute leukemia (AL) diagnostics. Nevertheless, lack of technological standards hampers implementation of immunophenotyping data in treatment protocols. Earlier our group published the acute lymphoblastic leukemia diagnostic standards. In this paper, we present the updated guidelines for initial immunophenotyping of ALs. This wellharmonized approach includes recommendations for monoclonal antibodies choice, sample preparation, cytometer setup, data analysis and interpretation as well as for the report writing. These guidelines allows application of diagnostic flow cytometric studies in all types of AL.
- 14 February 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (1) , 165-177
Open AccessFlow cytometry in acute leukemia diagnostics. Guidelines of Russian-Belarusian multicenter group for pediatric leukemia studies
Flow cytometry is one of the key technologies for acute leukemia (AL) diagnostics. Nevertheless, lack of technological standards hampers implementation of immunophenotyping data in treatment protocols. Earlier our group published the acute lymphoblastic leukemia diagnostic standards. In this paper, we present the updated guidelines for initial immunophenotyping of ALs. This wellharmonized approach includes recommendations for monoclonal antibodies choice, sample preparation, cytometer setup, data analysis and interpretation as well as for the report writing. These guidelines allows application of diagnostic flow cytometric studies in all types of AL.
- 1 January 2022
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 11 (4)
Application of CD27 AND CD44 expression for prediction of ETV6::RUNX1 fusion gene presence in pediatric B-CELL precursor acute lymphoblastic leukemia
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить возможность прогнозирования наличия транслокации t(12;21)(p13;q22)/ETV6::RUNX1 методом проточной цитометрии с использованием антигенов CD27 и CD44 у детей с острым лимфобластным лейкозом из B-линейных предшественников (ВП-ОЛЛ). МЕТОДЫ ИССЛЕДОВАНИЯ В исследование вошло 437 случаев ВП-ОЛЛ у детей в возрасте от 1 до 18 лет. Процентное количество CD27 и CD44 позитивных опухолевых клеток, а также средняя интенсивность флуоресценции (MFI) были сопоставлены с результатами молекулярно-генетических методов исследования. Оптимизация порогового уровня для определения позитивной экспрессии антигенов CD27 и CD44 была проведена с помощью ROC-анализа. РЕЗУЛЬТАТЫ Было доказано, что транслокация t(12;21)(p13;q22)/ETV6::RUNX1 ассоциирована с сочетанием позитивной экспрессии CD27 и сниженной, либо отсутствующей экспрессией CD44. Тем не менее, оптимальными пороговыми уровнями для определения позитивной экспрессии CD27 и CD44 в процентах оказались 80,7 и 86,1% соответственно. Использование отношения MFI CD27 к MFI CD44 показало наиболее высокий параметр диагностического отношения шансов — 953,1. ЗАКЛЮЧЕНИЕ Использование сочетания антигенов CD27 и CD44 позволило с высокой диагностической эффективностью предсказывать наличие t(12;21)(p13;q22)/ETV6::RUNX1 при ВП-ОЛЛ у детей методом проточной цитометрии.
- 1 January 2022
- Published by Media Sphere Publishing Group in Laboratory Service
- Vol. 11 (4)
Application of CD27 AND CD44 expression for prediction of ETV6::RUNX1 fusion gene presence in pediatric B-CELL precursor acute lymphoblastic leukemia
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить возможность прогнозирования наличия транслокации t(12;21)(p13;q22)/ETV6::RUNX1 методом проточной цитометрии с использованием антигенов CD27 и CD44 у детей с острым лимфобластным лейкозом из B-линейных предшественников (ВП-ОЛЛ). МЕТОДЫ ИССЛЕДОВАНИЯ В исследование вошло 437 случаев ВП-ОЛЛ у детей в возрасте от 1 до 18 лет. Процентное количество CD27 и CD44 позитивных опухолевых клеток, а также средняя интенсивность флуоресценции (MFI) были сопоставлены с результатами молекулярно-генетических методов исследования. Оптимизация порогового уровня для определения позитивной экспрессии антигенов CD27 и CD44 была проведена с помощью ROC-анализа. РЕЗУЛЬТАТЫ Было доказано, что транслокация t(12;21)(p13;q22)/ETV6::RUNX1 ассоциирована с сочетанием позитивной экспрессии CD27 и сниженной, либо отсутствующей экспрессией CD44. Тем не менее, оптимальными пороговыми уровнями для определения позитивной экспрессии CD27 и CD44 в процентах оказались 80,7 и 86,1% соответственно. Использование отношения MFI CD27 к MFI CD44 показало наиболее высокий параметр диагностического отношения шансов — 953,1. ЗАКЛЮЧЕНИЕ Использование сочетания антигенов CD27 и CD44 позволило с высокой диагностической эффективностью предсказывать наличие t(12;21)(p13;q22)/ETV6::RUNX1 при ВП-ОЛЛ у детей методом проточной цитометрии.